Heska Corp. (HSKA) Cut to “Hold” at Zacks Investment Research
According to Zacks, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products. “
HSKA has been the topic of a number of other reports. B. Riley downgraded shares of Heska Corp. from a buy rating to a neutral rating and upped their target price for the company from $52.50 to $53.00 in a research report on Wednesday, September 21st. Gabelli downgraded shares of Heska Corp. from a buy rating to a hold rating in a research report on Thursday, August 4th. Finally, Sidoti assumed coverage on shares of Heska Corp. in a research report on Friday, July 1st. They set a buy rating and a $49.00 target price on the stock. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Heska Corp. has a consensus rating of Buy and a consensus target price of $53.00.
Heska Corp. (NASDAQ:HSKA) opened at 54.85 on Wednesday. The company’s 50-day moving average is $53.88 and its 200-day moving average is $41.29. The stock has a market capitalization of $377.09 million, a P/E ratio of 55.57 and a beta of 0.41. Heska Corp. has a 12 month low of $26.26 and a 12 month high of $57.41.
Heska Corp. (NASDAQ:HSKA) last released its earnings results on Wednesday, August 3rd. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.17. Heska Corp. had a net margin of 6.22% and a return on equity of 8.75%. The company had revenue of $30 million for the quarter, compared to the consensus estimate of $28.47 million. Heska Corp.’s revenue was up 25.5% on a year-over-year basis. Equities analysts anticipate that Heska Corp. will post $1.12 earnings per share for the current year.
In related news, CEO Kevin S. Wilson sold 30,736 shares of the stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $47.34, for a total transaction of $1,455,042.24. Following the completion of the sale, the chief executive officer now directly owns 140,720 shares of the company’s stock, valued at approximately $6,661,684.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Jason A. Napolitano sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $52.53, for a total value of $262,650.00. The disclosure for this sale can be found here. 15.30% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY boosted its stake in Heska Corp. by 7.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,853 shares of the company’s stock worth $180,000 after buying an additional 320 shares during the last quarter. Highbridge Capital Management LLC acquired a new stake in Heska Corp. during the second quarter worth about $262,000. AQR Capital Management LLC boosted its stake in Heska Corp. by 73.0% in the second quarter. AQR Capital Management LLC now owns 30,401 shares of the company’s stock worth $1,130,000 after buying an additional 12,827 shares during the last quarter. A.R.T. Advisors LLC acquired a new stake in Heska Corp. during the second quarter worth about $317,000. Finally, Ranger Investment Management L.P. boosted its stake in Heska Corp. by 4.2% in the second quarter. Ranger Investment Management L.P. now owns 63,820 shares of the company’s stock worth $2,372,000 after buying an additional 2,580 shares during the last quarter. 68.32% of the stock is owned by institutional investors and hedge funds.
Heska Corp. Company Profile
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp. and related companies with MarketBeat.com's FREE daily email newsletter.